$3.30
4.72% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Inventiva - ADR Stock price

$3.30
-0.26 7.34% 1M
+0.56 20.39% 6M
+1.16 54.15% YTD
-0.41 10.98% 1Y
-6.00 64.53% 3Y
-10.12 75.42% 5Y
-10.12 75.42% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.15 4.72%
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Key metrics

Market capitalization $318.29m
Enterprise Value $274.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 27.56
P/S ratio (TTM) P/S ratio 31.96
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -47.32%
Revenue (TTM) Revenue $9.96m
EBIT (operating result TTM) EBIT $-107.59m
Free Cash Flow (TTM) Free Cash Flow $-93.38m
EPS (TTM) EPS $-3.33
P/E forward 19.39
P/S forward 17.44
EV/Sales forward 15.04
Short interest 0.49%
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Inventiva - ADR forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Inventiva - ADR forecast:

Buy
100%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
9.96 9.96
47% 47%
100%
- Direct Costs 3.88 3.88
42% 42%
39%
6.08 6.08
62% 62%
61%
- Selling and Administrative Expenses 15 15
6% 6%
147%
- Research and Development Expense 95 95
18% 18%
956%
-104 -104
9% 9%
-1,041%
- Depreciation and Amortization 3.88 3.88
42% 42%
39%
EBIT (Operating Income) EBIT -108 -108
8% 8%
-1,080%
Net Profit -199 -199
67% 67%
-2,001%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
GlobeNewsWire
16 days ago
Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announc...
Neutral
GlobeNewsWire
20 days ago
Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet ...
Neutral
GlobeNewsWire
26 days ago
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Employees 119
Founded 2011
Website www.inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today